QLT Shows Positive Efficacy Trends From Data in Plug Combinations in Phase II Studies for Glaucoma Using Latanoprost Punctal

QLT Shows Positive Efficacy Trends From Data in Plug Combinations in Phase II
Studies for Glaucoma Using Latanoprost Punctal Plug Delivery System

Announces Departure of Suzanne Cadden, Senior Vice President, Development

VANCOUVER, British Columbia, Oct. 24, 2012 (GLOBE NEWSWIRE) -- QLT Inc.
(Nasdaq:QLTI) (TSX:QLT) announced that results from two Phase II clinical
studies, PPL GLAU 12 and PPL GLAU 13, demonstrate positive trends (with
statistically and clinically significant findings) on the efficacy and safety
of the Latanoprost Punctal Plug Delivery System (L-PPDS) in subjects with
ocular hypertension (OH) and open-angle glaucoma (OAG).

"Clinical compliance with eye drops for the treatment of glaucoma is
recognized as a major therapeutic issue, particularly in the elderly, who
experience considerable difficulty in managing the use of an eye-drop bottle,"
said Jason Aryeh, Chairman of QLT. "The ability to deliver long lasting,
clinically significant intra ocular pressure lowering that is well tolerated
is, therefore, a significant therapeutic goal. Results from our PPL GLAU 12
and PPL GLAU 13 clinical trials suggest that clinically relevant IOP lowering
beyond 4 weeks may be achievable with a sustained release ophthalmic drug
delivery system, and that our proprietary upper plugs may improve upper plug
retention with certain design modifications.It remains a goal of QLT's Board
of Directors to advance research in the area and development of the PPDS
program through an out-licensing or sale."

Results in Detail

Efficacy

The two Phase II studies were initiated following results that also
demonstrated positive trends in a previous Phase II study (PPL GLAU 11)
showing clinically significant IOP lowering at 4 weeks with the L-PPDS.The
two new studies (PPL GLAU 12 and PPL GLAU 13) involved the simultaneous
placement of punctal plugs in both the upper and lower puncta for delivery of
a daily drug amount with a goal of enabling clinically significant, sustained
IOP lowering effects and comparable clinical outcomes to those of currently
marketed daily prostaglandin eye drops.

The primary endpoint of the studies was a mean reduction in IOP from baseline
(measured as mmHg) at 4 weeks, as influenced by drug dose (141 vs. 190
micrograms (µg) latanoprost per eye, Study PPL GLAU 12) and plug
placement/tearing effects (upper vs. lower puncta, and L-PPDS vs. plug with no
latanoprost drug core, Study PPL GLAU 13).Secondary endpoints were the IOP
change from baseline at other time points as well as the IOP and percentage
IOP change from baseline at all time points in the 12-week study period. In
the PPL GLAU 12 study, the effect of repeat treatment at the high dose (190
µg) was also assessed in a smaller group of subjects in two additional
treatment courses (occurring at 4 weeks and 8 weeks after the 12-week main
study).

A total of 57 ITT (Intent to Treat) subjects were included in PPL GLAU 12, and
77 ITT subjects were included in PPL GLAU 13. Two ITT datasets were analyzed,
one including all IOP values regardless of plug loss, and the other with IOP
excluded after first plug loss/removal. For both studies, mean IOP changes
from baseline were statistically significant at all time points. Across the 5
total treatment arms of both studies, 3 arms showed clinically significant IOP
lowering of 5 mmHg or greater at 4 weeks for both datasets, and 2 arms showed
clinically significant lowering of 5 mmHg or greater at 4 and 6 weeks for one
ITT dataset (IOP excluded after plug loss). During the 8-week second
treatment course in PPL GLAU 12 (n=38 eyes), the L-PPDS produced a
statistically and clinically significant reduction in mean IOP at 4 and 6
weeks. A lowering of IOP of 5 mmHg was the development plan objective for both
studies.

One arm (the 95 µg lower/blank plug upper configuration) showed a clinically
significant IOP lowering of approximately 5.0 mmHg at 4, 8 and 12 weeks for
both ITT datasets. This configuration, which demonstrated the most sustained
IOP reduction across all plug configurations and doses, suggests IOP lowering
with the L-PPDS as currently designed may be affected by the plug position
(and tearing effects) of these designs.Results of these studies also suggest
that double-plugging (simultaneous placement of both an upper and lower plug)
may be necessary to achieve a minimum IOP lowering effect using the current
design configurations.

Retention rate by eye of plugs in the lower puncta was >95% through week 12 in
PPL GLAU 12 and through week 10 in PPL GLAU 13 (week 12 retention was 92%).
Retention of upper plugs by eye was 69%, 53% and 48% at weeks 4, 8 and 12,
respectively, in PPL GLAU 12. In PPL GLAU 13, retention of upper plugs was
76%, 65% and 58% at weeks 4, 8 and 12, respectively. Rates of upper plug
retention increased across each subsequent month of the study for eyes
achieving plug retention at the previous 4 weeks. In the 8-week second
treatment course, upper plug retention was notably higher compared to the main
study, achieving values of 90 and 88% at 4 and 8 weeks, respectively.

Upper plug retention with the proprietary punctal plugs was notably improved
(approximately 19-33%) over the commercial plugs used in Study PPL GLAU 11. At
4 weeks, the upper plug retention by eye had increased from 48% in GLAU 11 to
67‑81% in PPL GLAU 12 and PPL GLAU 13.

Access to additional IOP clinical results of studies PPL GLAU 12 and PPL GLAU
13 are available on the Company's website at www.qltinc.com.

Safety and Tolerability

The L-PPDS was well tolerated over the testing period with adverse events
(AEs) similar to those reported for commercial punctal plugs and the previous
PPL GLAU 11 study. The majority of AEs were ocular in nature. In PPL GLAU 12
there were no associated AEs that were serious. In PPL GLAU 13 there were two
serious associated AEs (device extrusion and skin erosion) that occurred in
one subject.

Tearing and comfort were assessed by the subjects using a Visual Analogue
Scale (VAS), with 0 representing ratings of completely acceptable and 100
representing completely unacceptable. Across all treatment arms throughout the
duration of the studies tearing ratings were in the acceptable range (with
scores of approximately 20-30%) and comfort ratings were also in the
acceptable range (with scores of approximately 10-20%).

In PPL GLAU 12, 2 subjects discontinued from the study due to AEs, 17
discontinued due to plug loss, and 2 withdrew. All subjects were included in
the safety analysis.In PPL GLAU 13, 5 subjects discontinued from the study
due to AEs, 14 discontinued due to plug loss, 8 discontinued due to inadequate
IOP control and 1 withdrew. All subjects were included in the safety analysis.

Management Changes

QLT also announced today that Suzanne Cadden, Senior Vice President,
Development, will be leaving the Company.The Company's research and
development responsibilities will be assumed by Sushanta Mallick, PhD.Dr.
Mallick joined QLT in October, 2012 and brings to the Company almost 20 years
of clinical and product development experience at Alcon Research, Ltd.Over
the course of his employment at Alcon, Dr. Mallick held various positions of
increasing responsibility, specializing in the glaucoma, retina and dry eye
therapeutic areas.Dr. Mallick received his PhD in Biochemistry from the
University of North Texas and his MBA from the University of Texas at Dallas.

"We thank Ms. Cadden for her efforts and commitment to the company and wish
her the best in her future endeavors," commented Mr. Aryeh."Dr. Mallick and
the rest of the clinical team are acutely focused on QLT's synthetic oral
retinoid program, which we look forward to progressing toward potential
pivotal trials in 2013, following analysis of results from our ongoing
retreatment studies."

About PPL GLAU 12

This completed Phase II multicenter study was conducted to evaluate the safety
and efficacy of the L-PPDS utilizing simultaneous placement of punctal plugs
in the upper and lower puncta containing a combined total of either 141 µg or
190 µg of latanoprost, a prostaglandin analogue, in subjects with ocular
hypertension (OH) or open-angle glaucoma (OAG) over a 12-week period. Subjects
who met criteria for repeat treatment were eligible to undergo subsequent
L-PPDS treatment courses at a dose of 190 µg for an 8-week period, followed by
a 4-week period.

About PPL GLAU 13

This completed Phase II multicenter study was conducted to evaluate the safety
and efficacy of the L-PPDS utilizing 3 different plug placement configurations
delivering 95 µg of latanoprost, a prostaglandin analogue, in subjects with
ocular hypertension (OH) or open-angle glaucoma (OAG) over a 12-week period.
Subjects received different treatments in each eye. The 3 configurations were
1) a blank plug (no latanoprost drug core) in the lower punctum and a 95 µg
L-PPDS in the upper punctum, 2) an open lower punctum (no plug) and a 95 µg
L-PPDS in the upper punctum, and 3) a 95 µg L-PPDS in the lower punctum and a
blank plug in the upper punctum.

About QLT

QLT is a biotechnology company dedicated to the development and
commercialization of innovative ocular products that address the unmet medical
needs of patients and clinicians worldwide. We are focused on developing our
synthetic retinoid program for the treatment of certain inherited retinal
diseases.

QLT's head office is based in Vancouver, Canada and the Company is publicly
traded on NASDAQ (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT).
For more information about the Company's products and developments, please
visit our web site at www.qltinc.com.

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI"
and on The Toronto Stock Exchange under the trading symbol "QLT."

The QLT Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6933

Certain statements in this press release constitute "forward-looking
statements" of QLT within the meaning of the Private Securities Litigation
Reform Act of 1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. Forward-looking statements
include, but are not limited to: statements concerning the potential benefits,
efficacy and safety of the L-PPDS for treatment of OH and OAG; statements
concerning the potential divestment of the punctal plug drug delivery system
program (PPDS); and statements which contain language such as: "assuming,"
"prospects," "goal," "future," "projects," "potential," "believes," "expects";
"hopes" and "outlook." Forward-looking statements are predictions only which
involve known and unknown risks, uncertainties and other factors that may
cause actual results to be materially different from those expressed in such
statements. Many such risks, uncertainties and other factors are taken into
account as part of our assumptions underlying these forward-looking statements
and include, among others, the following: risks and uncertainties related to
the timing and our ability to divest the PPDS program on terms favorable to us
or at all; risks and uncertainties concerning the impacts that QLT's strategic
initiatives will have on the market price of our securities; uncertainties
relating to our development plans, timing and results of the clinical
development and commercialization of our products and technologies;
assumptions related to continued enrollment trends, efforts and success, and
the associated costs of these programs; outcomes for our clinical trials
(including our PPDS technology and our synthetic retinoid program) may not be
favorable or may be less favorable than interim/preliminary results and/or
previous trials; there may be varying interpretations of data produced by one
or more of our clinical trials; the timing, expense and uncertainty associated
with the regulatory approval process for products to advance through
development stages; risks and uncertainties associated with the safety and
effectiveness of our technology; risks and uncertainties related to the scope,
validity, and enforceability of our intellectual property rights and the
impact of patents and other intellectual property of third parties; the
Company's future operating results are uncertain and likely to fluctuate;
currency fluctuations; and general economic conditions and other factors
described in detail in QLT's Annual Report on Form 10-K, Quarterly Reports on
Form 10-Q and other filings with the U.S. Securities and Exchange Commission
and Canadian securities regulatory authorities.Forward-looking statements are
based on the current expectations of QLT and QLT does not assume any
obligation to update such information to reflect later events or developments
except as required by law.

CONTACT: QLT Inc. Contacts:
        
         Investor & Media Relations
         Andrea Rabney or David Pitts
         Argot Partners
         212-600-1902
         andrea@argotpartners.com
         david@argotpartners.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.